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Objectives: To evaluate the role of intraoperative an-
eurysm sac embolization during EVAR (edEVAR) with
coils and glue, in the prevention of Endoleak type II (ET2).
Methods: Two groups were compared: 85 patients under-
went standard EVAR during 2007-2008 (Group A) and 81
patients underwent edEVARduring2009-2010 (GroupB).CT
scans were elaborated with the Osirix 4.0 software in order to
obtain aneurysm sac volume. ET2 rates at the first CT scan
follow-up, as mid-term free from ET2 and free from related
reintervention were compared. Preoperative patent number of
aortic side branches (IMA, lumbars, accessories renal), thrombus
and sac volume were evaluated for their association with ET2 in
the two groups, using multivariate analysis.
Results: Patients characteristics, Society for Vascular
Surgery (SVS) comorbidity score (0.850.44 vs
0.820.48; P  .68) and operative time (185.451.8 vs
172.950.8;P .99) were similar between group A and B.
The first CT scan (or  2 months) demonstrated signif-
icantly higher number of ET2 in group A compared to
group B (23.5% vs 9.8%;P  .02). Spontaneous ET2 reso-
lution occurred in 65% of patients in Group A and 79% in
group B (P  1.0), while sac volume increased in 25% vs
10% (P .63) of cases respectively. At 18 months (range:6
to 24) overall mean difference in sac volume shrinkage
(27.212.3 cm3 vs 24.811.6 cm3; P  .19) and free
from ET2 (91.8% vs 96.3%; P  0.33) were similar, while
free from reintervention was significantly lower in Group A
(94.1% vs 98.8%; P  .05) compared to Group B. Multi-
variate analysis showed preoperative aneurysm sac volume
 125 cm3 to be the only independent significant predictor
of ET2 (OR, 3.64; 95% CI, 1.54 to 8.58; P  .003).
Conclusions:EdEVAR seems to be a valid approach to
prevent ET2 and its complications during short and mid-
term follow-up. Patients with preoperative aneurysm sac
volume higher than 125 cm3 should be considered for a
more aggressive intraoperative embolization.
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Objectives: Alvimopan is a peripherally acting mu-opioid
antagonist used to shorten the time to return of gastrointestinal
function after surgery. Randomized clinical trials have demon-
strated a shorter time period to return of bowel function and
discharge in open abdominal colonic surgeries, but nodata exists
on its use in the aortic vascular surgery population.
Methods: Alvimopan was administered to patients hav-
ing open abdominal aortic aneurysm repair or aortofemoral
bypass. The administration protocol was one 12 mg dose
preoperatively and doses of 12mg twice a day postoperatively
until the first bowel movement or a total of seven days. There
were seven patients in the study group and 6 patients in the
control group. The primary end points were time to regain
bowel function and length of hospital stay.
Results: The average age (Study  69.3  3.8 years vs.
Control 68.5 3.4 years; P  .88), abdominal aortic aneu-
rysm size (Study 5.9 0.3 cm vs. Control 5.3 0.5 cm;P
 .28), procedure time (Study2.10.1 hours vs. Control
2.6 0.3 hours;P .12), gender and comorbidities were not
different between the two cohorts. There is a quicker time to
regain bowel function (Study 2.9 0.4 days vs. Control
4.5  0.6 days; P  .04) and shorter hospitalization (Study
5.60.3days vs.Control6.80.4days;P .03) in the
study group compared to the control group.
Conclusions: These preliminary data show that peri-
operative Alvimopan benefits patients, resulting in quicker
time to regain bowel function and shorter hospitalization,
consistent with previous studies involving open abdominal
bowel resection. This improved resource utilization sup-
ports further investigation via a large scale randomized
pharmacoeconomic endpoint trial.
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Objectives: Aortic coarctation is one of themost common
congenital aortic lesionsand isusually repaired inearlychildhood.
Without correction, death often occurs before the fourth decade
and surviving adults suffer from hypertension and other compli-
cations from poor distal flow.We report on our experience with
open repair of aortic coarctation in adults.
Methods:We retrospectively reviewed all patients age16
years requiring open repair (de novo and redo) of aortic coarcta-
tion.Ourprotocol for spinal cordprotection includesdistal aortic
perfusionvia atriofemoral bypass,moderatepassivehypothermia,
and cerebrospinal fluid drainage. Indications for repair, operative
details, and outcomes were analyzed.
Results: Between 1999 and 2011, we treated 30 patients
withadult aortic coarctation.Themedianagewas40years (range
17-69) and there were 16 males. Eight patients had previous
repair with recurrence; 22 patients had native coarctation. Aortic
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